Jayson Bedford
Stock Analyst at Raymond James
(3.83)
# 667
Out of 5,152 analysts
324
Total ratings
54.07%
Success rate
7.26%
Average return
Main Sectors:
Stocks Rated by Jayson Bedford
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AXGN Axogen | Maintains: Outperform | $20 → $27 | $28.70 | -5.92% | 2 | Oct 30, 2025 | |
| ISRG Intuitive Surgical | Maintains: Outperform | $592 → $603 | $486.71 | +23.89% | 9 | Oct 22, 2025 | |
| CBLL CeriBell | Initiates: Strong Buy | $19 | $17.46 | +8.82% | 1 | Oct 21, 2025 | |
| ABT Abbott Laboratories | Maintains: Outperform | $141 → $146 | $108.69 | +34.33% | 30 | Oct 16, 2025 | |
| JNJ Johnson & Johnson | Maintains: Outperform | $174 → $209 | $238.38 | -12.32% | 24 | Oct 15, 2025 | |
| ZBH Zimmer Biomet Holdings | Maintains: Outperform | $104 → $113 | $93.49 | +20.87% | 9 | Aug 8, 2025 | |
| ICUI ICU Medical | Maintains: Strong Buy | $187 → $180 | $131.52 | +36.86% | 22 | Aug 8, 2025 | |
| MMSI Merit Medical Systems | Maintains: Outperform | $108 → $102 | $73.40 | +38.96% | 28 | Jul 31, 2025 | |
| DXCM DexCom | Maintains: Strong Buy | $99 → $102 | $67.85 | +50.33% | 31 | Jul 31, 2025 | |
| BSX Boston Scientific | Maintains: Strong Buy | $121 → $124 | $71.49 | +73.45% | 26 | Jul 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $328 → $360 | $234.63 | +53.43% | 27 | May 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $204 → $185 | $175.48 | +5.43% | 7 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $275 → $270 | $168.36 | +60.37% | 3 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $10 | $10.64 | -6.02% | 14 | Jan 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $227 → $271 | $114.73 | +136.20% | 12 | Dec 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $12.39 | - | 10 | Nov 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $21.25 | - | 13 | Apr 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $81.35 | - | 20 | Feb 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $17.91 | - | 6 | Jan 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $90.88 | - | 14 | Aug 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $5.97 | - | 4 | Mar 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $75 → $86 | $75.69 | +13.63% | 4 | Nov 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.40 | - | 5 | Aug 2, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $9.54 | - | 3 | Jan 2, 2018 |
Axogen
Oct 30, 2025
Maintains: Outperform
Price Target: $20 → $27
Current: $28.70
Upside: -5.92%
Intuitive Surgical
Oct 22, 2025
Maintains: Outperform
Price Target: $592 → $603
Current: $486.71
Upside: +23.89%
CeriBell
Oct 21, 2025
Initiates: Strong Buy
Price Target: $19
Current: $17.46
Upside: +8.82%
Abbott Laboratories
Oct 16, 2025
Maintains: Outperform
Price Target: $141 → $146
Current: $108.69
Upside: +34.33%
Johnson & Johnson
Oct 15, 2025
Maintains: Outperform
Price Target: $174 → $209
Current: $238.38
Upside: -12.32%
Zimmer Biomet Holdings
Aug 8, 2025
Maintains: Outperform
Price Target: $104 → $113
Current: $93.49
Upside: +20.87%
ICU Medical
Aug 8, 2025
Maintains: Strong Buy
Price Target: $187 → $180
Current: $131.52
Upside: +36.86%
Merit Medical Systems
Jul 31, 2025
Maintains: Outperform
Price Target: $108 → $102
Current: $73.40
Upside: +38.96%
DexCom
Jul 31, 2025
Maintains: Strong Buy
Price Target: $99 → $102
Current: $67.85
Upside: +50.33%
Boston Scientific
Jul 24, 2025
Maintains: Strong Buy
Price Target: $121 → $124
Current: $71.49
Upside: +73.45%
May 27, 2025
Maintains: Outperform
Price Target: $328 → $360
Current: $234.63
Upside: +53.43%
May 7, 2025
Maintains: Outperform
Price Target: $204 → $185
Current: $175.48
Upside: +5.43%
Aug 2, 2024
Maintains: Outperform
Price Target: $275 → $270
Current: $168.36
Upside: +60.37%
Jan 9, 2024
Maintains: Outperform
Price Target: $12 → $10
Current: $10.64
Upside: -6.02%
Dec 20, 2023
Maintains: Outperform
Price Target: $227 → $271
Current: $114.73
Upside: +136.20%
Nov 16, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $12.39
Upside: -
Apr 24, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $21.25
Upside: -
Feb 6, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $81.35
Upside: -
Jan 5, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $17.91
Upside: -
Aug 24, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $90.88
Upside: -
Mar 5, 2021
Downgrades: Underperform
Price Target: n/a
Current: $5.97
Upside: -
Nov 5, 2020
Maintains: Outperform
Price Target: $75 → $86
Current: $75.69
Upside: +13.63%
Aug 2, 2019
Downgrades: Market Perform
Price Target: n/a
Current: $1.40
Upside: -
Jan 2, 2018
Downgrades: Market Perform
Price Target: n/a
Current: $9.54
Upside: -